CONTRIBUTORS

John J. Doski, MD
Pediatric General and Thoracic Surgery
San Antonio Pediatric Surgery Associates
San Antonio, TX

Peter F. Ehrlich, MD
Associate Professor
University of Michigan CS Mott Children's Hospital
Ann Arbor, MI

Thomas Hamilton, MD
Assistant Program Director, Pediatric Surgery
Boston Children’s Hospital
Boston, MA

Robert C. Shamberger, MD
Chief of Surgery
Children's Hospital Boston
Boston, MA

Michael Ritchey
University of Texas Medical School
Houston, TX
NOTICE

The authors, editors, and APSA disclaim any liability, loss, injury or damage incurred as a consequence, directly or indirectly, of the use or application of any of the contents of this volume. While authors and editors have made every effort to create guidelines that should be helpful, it is impossible to create a text that covers every clinical situation that may arise in regards to either diagnosis and/or treatment. Authors and editors cannot be held responsible for any typographic or other errors in the printing of this text. Any dosages or instructions in this text that are questioned should be cross referenced with other sources.

Attending physicians, residents, fellows, students and providers using this handbook in the treatment of pediatric patients should recognize that this text is not meant to be a replacement for discourse or consultations with the attending and consulting staff. Management strategies and styles discussed within this text are neither binding nor definitive and should not be treated as a collection of protocols.
TABLE OF CONTENTS

1. Introduction
2. One-Minute Review
3. Staging - Wilms'
4. Staging - Renal Cell Carcinoma
5. Operative Procedures Primary Tumor
6. Lymph Node Documentation
7. Tumor Biopsy
8. Tumor Spillage
9. Renal Vein/Inferior Vena Cava
10. Surgical Management of Metastases
11. Initially Unresectable Tumors
12. Operative Procedures for Bilateral Tumors
INTRODUCTION

This handbook provides you with the current surgical management of Renal Tumors. It is based on current literature and accepted practice, and is managed and updated by the APSA Cancer Committee. It is designed to consolidate the most current and up to date material you need to know when treating your patient. Renal Tumor treatment is centered on risk stratification according to histopathology, surgical stage, loss of heterozygosity, and response to treatment.

This handbook begins with A One Minute Review which is designed for use immediately before an operation and includes abbreviated staging, risk stratification, surgery guidelines, and tissue handling. There follows more descriptive sections for in depth staging and surgical management for all stages of renal tumors, including bilateral (stage V).

Much of this knowledge has been discovered by strong clinical trials as the National Wilms’ Tumor Study Group (NWTS I-V) and Renal Tumor Protocols with the Children’s Oncology Group. Enrollment on open biologic and clinical trials with the Children’s Oncology Group is strongly encouraged.

Surgery Study members are listed below, and should be contacted for questions. Any and all suggestions for improvement are welcome.

APSA Pediatric Surgical Contacts for Questions:

Peter Ehrlich, MD (734) 764-6482 pehrlich@med.umich.edu
Thomas Hamilton (207) 772-4444 Thomas.Hamilton@childrens.harvard.edu
Michael Ritchey (602) 264-0461 michael.ritchey@gmail.com
Robert Shamberger (617) 355-8326 Robert.Shamberger@childrens.harvard.edu
RENAL TUMORS – ONE-MINUTE REVIEW

STAGES

I  Tumor limited to kidney, completely resected.
II Tumor extends beyond kidney, completely resected.
III Residual non-Hematogenous tumor present, confined to abdomen or retroperitoneal lymph node involvement.
IV Hematogenous metastases (lung, liver, bone, brain) or extraabdominal LN metastases.
V Bilateral renal involvement.

SURGICAL PRINCIPLES

Stages I-IV

Complete abdominal exploration. Unilateral radical nephrectomy with lymph node sampling via transperitoneal incision. Avoid rupture or spillage by use of adequate incision. Flank incision should not be utilized. Palpate renal vein and IVC for extension. Visualization and palpation of contralateral kidney not necessary if imaging normal. Ureter is ligated and divided as low as conveniently possible. Titanium clips used only to identify residual tumor, margins of dissection, and suspicious areas. DO NOT BIOPSY TUMOR.

Lymph node sampling should include renal hilar, paraaortic and/or paracaval nodes, as well as any suspicious nodes. Lymph node sampling must be pursued and established to confirm node negative status for treatment. For tumors believed unresectable at initial operation, adequate biopsy should be performed.

Stage V

NO initial biopsy. Start with upfront 3 drug chemotherapy, vincristine, actinomycin D, and doxorubicin. Reevaluate at 6 wks for possible biopsy if <50% reduction in size, (or resect if resectable), vs continued chemotherapy with operation at 12 weeks, nephrectomy if kidney not salvageable.

TISSUE HANDLING

Do Not Bivalve or otherwise disrupt capsule in OR. Send intact specimen FRESH
STAGING

**Stage I** - Tumor limited to kidney, completely resected. The renal capsule is intact. The tumor was not ruptured or biopsied prior to removal. The vessels of the renal sinus are not involved. There is no evidence of tumor at or beyond the margins of resection. NOTE: For a tumor to be considered Stage I, regional lymph nodes must be examined microscopically.

**Stage II** - The tumor is completely resected and there is no evidence of tumor at or beyond the margins of resection. The tumor extends beyond kidney, as is evidenced by any one of the following criteria:

- There is regional extension of the tumor (i.e. penetration of the renal capsule, or extensive invasion of the soft tissue of the renal sinus, as discussed below)
- Blood vessels within the nephrectomy specimen outside the renal parenchyma, including those of the renal sinus, contain tumor.

Note: Rupture or spillage confined to the flank, including biopsy of the tumor, is no longer Stage II. It is Stage III.

**Stage III** - Residual non-hematogenous tumor present following surgery, and confined to abdomen. Any one of the following may occur:

- Lymph nodes within the abdomen or pelvis are involved by tumor. (Lymph node involvement in the thorax, or other extra-abdominal sites is a criterion for stage IV),
- The tumor has penetrated through the peritoneal surface,
- Tumor implants are found on the peritoneal surface,
- Gross or microscopic tumor remains post-operatively (e.g., tumor cells are found at the margin of surgical resection on microscopic examination),
- The tumor is not completely resected because of local infiltration into vital structures,
- Tumor spillage occurring either before or during surgery,
- The tumor was biopsied (whether, true-cut, open or fine needle aspiration) before removal,
- Tumor is removed in more than one piece (e.g. tumor cells are found in a separately excised adrenal gland; a tumor thrombus within the renal vein is removed separately from the nephrectomy specimen).

**Stage IV** - Hematogenous metastases (lung, liver, bone, brain, etc.), or lymph node metastases outside the abdomino-pelvic region are present. (The presence of tumor within the adrenal gland is not interpreted as metastasis and staging depends on all other staging parameters present).

**Stage V** - Bilateral renal involvement by tumor is present at diagnosis. An attempt should be made to stage each side according to the above criteria on the basis of the extent of disease.
Staging of Renal Cell Carcinoma by the TNM system:

T--Primary Tumor
TX  Primary tumor cannot be assessed
T0  No evidence of primary tumor
T1  Tumor 7.0 cm or less in greatest dimension, limited to the kidney
T2  Tumor more than 7.0 cm in greatest dimension, limited to the kidney
T3  Tumor extends into major veins or invades adrenal gland or perinephric tissues but not beyond Gerota’s fascia
    T3a  Tumor invades adrenal gland or perinephric tissues but not beyond Gerota’s fascia
    T3b  Tumor grossly extends into renal vein(s) or vena cava below diaphragm
    T3c  Tumor grossly extends into vena cava above diaphragm
T4  Tumor invades beyond Gerota’s fascia

N--Regional Lymph Nodes (Hilar, abdominal para-aortic, and paracaval nodes. Laterality has no effect):
NX  Regional lymph nodes cannot be assessed
N0  No regional lymph node metastasis
N1  Metastasis in a single regional lymph node
N2  Metastasis in more than one regional lymph node

M--Distant Metastasis
MX  Distant metastasis cannot be assessed
M0  No distant metastasis
M1  Distant metastasis

Stage Grouping for Renal Cell Carcinoma:

Stage I  T1  N0  M0
Stage II T2  N0  M0
Stage III T1  N1  M0
    T2  N1  M0
    T3  N0 or N1 M0
Stage IV T4  N0, N1 M0
    Any T  N2  M0
    Any T  Any N M1
Operative Procedure for Primary Tumor

Primary Nephrectomy, Stage I-IV

A generous transabdominal, transperitoneal or thoracoabdominal incision is recommended for adequate exposure. Complete exploration of the abdomen should be performed. A radical nephrectomy is performed with the ureter divided as distally as possible. Routine exploration of the contralateral kidney is not necessary if technically adequate imaging does not suggest a bilateral process. (For surgical guidelines for bilateral tumors see next section) If the initial imaging studies are suggestive of a lesion on the contralateral kidney, the contralateral kidney should be formally explored to rule out bilateral involvement. This should be done prior to nephrectomy since the diagnosis of bilateral disease dramatically alters the therapeutic approach and may contra indicate initial nephrectomy. To do this exploration adequately, the colon and its mesentery should be mobilized from the anterior surface of the contralateral kidney, Gerota's fascia incised, and the kidney turned forward to palpate and visualize both its anterior and posterior surfaces. Any areas suggestive of bilateral involvement should be biopsied. See procedures for tumor biopsy below.

To expose the primary tumor, the lateral peritoneal reflection is then opened, and the colon is reflected medially. A plane is established outside of Gerota's fascia by sharp and blunt dissection. Before mobilizing the primary tumor, an attempt should be made to dissect, expose and ligate the renal vessels in order to lessen the chance of hematogenous spread of tumor cells while removing the tumor. Preliminary ligation should not be pursued if technically difficult or dangerous due to tumor size or extensive lymph node involvement. The adrenal gland may be left in place if it is not abutting the tumor; but, if the mass arises in the upper pole of the kidney, the adrenal gland should be removed with the neoplasm. The ureter is ligated and divided as low as conveniently possible, but it is not necessary to remove the entire ureter. The tumor and the uninvolved portion of the kidney are mobilized and removed intact. Any enlarged or suspicious lymph nodes should be included with the specimen.

The use of titanium clips is strongly recommended to identify gross residual tumor. Clips should not be used for hemostasis and those placed for roentgenographic identification or radiation therapy portals should be limited to the minimum number necessary. Metallic clips can interfere with the CT scan. Clips are best applied by placing a non-absorbable suture in the structure to be marked, and attaching the clip to the suture. In general four small clips should be sufficient to delineate the margins of the tumor.

Any suspicious areas that could represent metastases should be biopsied, the site(s) identified with small titanium clips so that the locations can be determined later by roentgenograms.

The involved areas should be drawn on the diagram in the surgical checklist. The specimen should be specifically identified as to the site from which it was removed.

Contiguous Organs

Wilms' tumors are frequently adherent to adjacent organs. In the majority of cases, there is not frank invasion by the tumor. Radical en bloc resection, e.g. partial hepatectomy is not generally warranted. Extensive resection including multiple organs, e.g. spleen, pancreas, and colon, is
also not advised as this is associated with an increased frequency of complications. If removal of a small section of diaphragm, psoas muscle, or tip of the pancreas allows the tumor to be removed intact, then proceed.

**Partial Nephrectomy (for Stages I-IV)**

Partial nephrectomy is not indicated in the routine patient with unilateral Wilms’ tumor. The exception is the child with a Wilms’ tumor-predisposing syndrome (eg. WAGR, Beckwith Wiedemann, Denys Drash etc) who although presenting with a unilateral tumor is predisposed to the subsequent development of contralateral disease. Hence, such children need to be managed with a renal sparing approach as for bilateral tumors.

**Lymph Node Documentation**

The presence or absence of disease in hilar and regional lymph nodes is an extremely important factor in accurate staging and therefore appropriate treatment. Routine lymph node sampling from the renal hilum and the paracaval or paraaortic areas must be done for accurate staging, especially for those patients being considered for surgical resection alone. Involved or suspicious lymph nodes should be excised. Formal lymph node dissection is not recommended. Label the nodes carefully for separate microscopic examination. All lymph nodes removed should be identified on the surgical check list and the accompanying diagram.

**Assignment of Surgical Stage**

The surgeon should assign a "local-regional stage" to the tumor based solely on the operative findings and findings on pathologic examination. Knowledge of distant metastases does not influence local surgical staging. For example, the patient would be evaluated as "surgical stage III" if there were obviously positive lymph nodes even if it were known that pulmonary metastases were also present.

**Tumor Biopsy**

Routine pre-nephrectomy tumor biopsies are contraindicated. Studies have shown a higher risk of recurrence in patients who had tumor spills or ruptures irrespective of the cause or extent of the soiling. These events result in an increased risk of local recurrence and increased adjuvant therapy with those attendant risks. Tumor biopsy prior to nephrectomy is considered local spill which results in children receiving additional chemotherapy (doxorubicinn) and flank radiation to 10cGy.

**Preoperative and intraoperative biopsies are therefore contraindicated and should only be performed when a tumor is deemed unresectable.** If a biopsy is obtained, a posterior approach is advised to limit contamination of the peritoneal cavity. Needle biopsies are acceptable.
**Tumor Spillage**

It is important for accurate staging to document the extent of any peritoneal soilage by tumor since this will determine the need for radiation therapy. The peritoneum shall be considered "soiled" if there has been a biopsy (either pre operative or intra operative) in a tumor that is subsequently removed at initial surgery, if there has been preoperative rupture, if there is a tumor spill or if the tumor has been removed in more than one piece. Local spills are defined as those limited to the renal fossa. Diffuse spills are those occurring beyond these limits. All instances of soilage will be classified as stage III, but local soilage will be treated with flank irradiation only while diffuse soilage will be managed with whole abdominal irradiation field.

Spillage refers to transgression of the tumor capsule during operative removal whether accidental, unavoidable or by design. Tumors and adherent tissues that are removed en bloc should produce no tumor spill. However, tumor tissue may be cut across during removal of adherent structures or during removal of lymph nodes. Tumors that are removed in more than one piece, the neoplastic tissue having been cut across in the process, shall be considered to have been spilled. Spill would also occur if the surgeon transected the renal vein or ureter at the site of tumor extension. In any of these instances, the surgeon should indicate whether in their opinion the peritoneal soilage was local (confined to the renal fossa) or diffuse.

Preoperative percutaneous needle biopsy from the anterior or posterior approach shall be considered local spillage. Open incisional biopsy prior to nephrectomy shall be considered a local spill unless, in the surgeon's judgment, the whole peritoneal cavity has been soiled in the process. The technique and timing of biopsy should be described fully in the operative note to assist reviewers in assessing the prognostic impact of such biopsies.

Rupture refers to either the spontaneous or post-traumatic rupture of the tumor preoperatively with the result that tumor cells are disseminated throughout the peritoneal cavity. Bloody peritoneal fluid shall be considered a sign of rupture, whether or not gross or microscopic tumor is identified in the fluid. There are times when the tumor may rupture posteriorly and the perforation is confined to the retroperitoneal space, thus qualifying as local soilage. When a hematoma is present, it is assumed that tumor cells will spread with the blood. If primary nephrectomy is undertaken, this increases the risk of contamination of the peritoneal space. Staging of such patients is problematic. The superior, inferior, medial and lateral margins of the associated hematoma should be described fully in the operative note, and the margins marked with titanium clips. Tumor may penetrate the kidney capsule, and the overlying peritoneum, the raw neoplastic tissue surface being in free communication with the peritoneal cavity. This shall be considered diffuse soilage. Separate, distinct nodules of tumor on the peritoneal or serosal surfaces, at a distance from the primary neoplasm ("satellite implants") shall be considered a sign of diffuse soilage.

Complete description of all techniques is essential. Please provide clear statements regarding how soilage of the peritoneal cavity occurred, and unequivocal opinion regarding whether soilage was diffuse or local.

When tumor extends into the renal vein or inferior vena cava, a precise description of the technique of removal should be given in the operative note. It must be stated in the operative report if the intravascular tumor extension was removed en bloc or if tumor was transected.
during the resection. It must also be clear whether the tumor thrombus has been removed completely and if there is evidence of either adherence or invasion of the vein wall.

**Renal Vein/Inferior Vena Cava**

Vascular invasion of the renal vein, cava and atrium presents special surgical challenges, and, since these tumors will often respond to preoperative therapy, management requires careful consideration. Renal vein involvement has been noted in 11% of cases (most often detected at operation) and caval and atrial involvement in 5% of Wilms’ tumor cases. The pre operative ultrasound and CT scan will usually identify intravascular tumor extension but the renal vein and inferior vena cava should still be palpated carefully before ligation to rule out extension of the tumor into the vein.

Tumor extension into the renal vein and proximate inferior vena cava can in most cases be removed en-bloc with the kidney. However, primary resection of tumors that extend up the inferior vena cava above the level of the hepatic veins and particularly to the atrium is associated with higher operative morbidity. In these circumstances, preoperative chemotherapy decreases the size and extent of the tumor thrombus facilitating subsequent excision.

The tumor that extends into the renal vein and cava may simply extend as a floating attachment and can then be “fished out”. Control of the renal vein and cava above and below the tumor with vessel loops is essential. Silk 2-0 stitches can then be placed on either side of the renal vein. This will help with vascular control and limit bleeding. The tumor and kidney should be completely mobilized prior to removing a vascular thrombus. A venotomy is then created and the tumor pulled out of the vein. A foley balloon technique can also be used to pull out the tumor. The tumor should not be transected.

In other instances the tumor may be fixed to the vascular lumen. Extraction is more difficult and a larger venotomy may be required. A similar technique used for removing plaque for a carotid endarterectomy is helpful to lift the tumor off the vein wall. If after preoperative chemotherapy the tumor still extends above the hepatic veins, cardiopulmonary bypass is required to remove the intravascular extent of the tumor. The abdominal tumor is mobilized and removed first prior to administration of heparin. After placing the child on bypass the right atrium is opened and the tricuspid value inspected. The tumor is removed from the heart above and below at the same time to prevent tumor emboli.

**Surgical Management of Metastases**

**Intra-abdominal Metastases**

Any suspicious site in the abdomen or liver should be biopsied or resected at exploration to determine the nature of the mass as it will affect tumor stage and therapy. If residual intra-abdominal metastatic disease remains at week 12 of chemotherapy, it should be resected if complete resection is feasible. If complete resection is not feasible, then residual disease should be reassessed for feasibility of resection at the completion of therapy.

**Pulmonary Metastases**

It is strongly recommended that if there is any doubt about the nature of pulmonary nodules that these be biopsied since as many as one third of small (<1 cm) lesions may not be metastatic
tumor. Note however, that stage III and IV patients will receive the same chemotherapy for the first six weeks. Only patients with residual pulmonary lesions at this time will receive whole lung radiation. Thus it is only for patients with local stage I and II tumors that it is critical to define the nature of small pulmonary lesions at diagnosis.

It is strongly recommended to biopsy residual pulmonary lesions at week six if there is any doubt about the nature of the lesions prior to committing the patient to whole lung radiation and intensification of chemotherapy. Patients will still receive intensified therapy however, even if all disease is surgically resected.

Most metastases are peripheral and superficial and can be removed thoracoscopically. For larger lesions (e.g. right middle lobe mass) or for those wishing to perform an open procedure, a standard posterior lateral thoracotomy incision for exploration of the chest can be used.

If pulmonary nodules remain after Week 12 of chemotherapy (and irradiation), they should be resected if complete resection is feasible. If complete resection is not feasible, then imaging studies should be repeated at the end of protocol therapy to reassess for feasibility of resection.

Bone Metastases

Surgical resection of bone metastases is rarely recommended and should be considered only if such would result in removal of all known disease. Bone metastases are treated primarily with radiation therapy.

Brain Metastases

Surgical resection of brain metastases may be considered before the initiation of chemotherapy if complete resection is feasible.

Initially Unresectable Renal Tumors

Past experience in the NWTSG and the studies conducted by the International Society of Pediatric Oncology have shown that pretreatment with chemotherapy almost always reduces the bulk of the tumor and renders it more safely resectable while often allowing preservation of the contiguous organs. However, this method does not result in improved survival rates, and does result in the loss of important staging information. It is recommended therefore that all patients undergo initial exploration to assess operability. It is only then that a tumor biopsy should be considered, if safe resection is not feasible. Thorough exploration of the abdomen is necessary to detect evidence of extrarenal extension of tumor. If suspicious lymph nodes or other metastatic deposits are found, these should be biopsied to document tumor involvement. Patients who are staged by imaging studies alone are at risk for understaging and overstaging. If pre-nephrectomy therapy is given based on imaging alone, with or without a needle biopsy, the local tumor should be considered to be stage III. In general, radiographic reevaluation should be performed at week 6. The operative procedure can be performed shortly thereafter if sufficient tumor shrinkage has occurred. Serial imaging evaluation is helpful to assess response, but radiographic evidence of persistent disease can occasionally be misleading. Little additional tumor regression can be expected after 4 courses of chemotherapy.
Tumors should be considered unresectable if:

- There is extension of tumor thrombus above the level of the hepatic veins. These patients should be considered for tumor resection when there is evidence of regression of the vena caval thrombus regardless of the degree of response of the primary tumor.
- The tumor involves contiguous structures whereby the only means of removing the kidney tumor requires removal of the other structure (e.g. spleen, pancreas, colon but excluding the adrenal gland). Note however, that Wilms’ tumors are frequently adherent to adjacent organs. In the majority of cases, there is not frank invasion by the tumor and the organs can be dissected freely from the tumor. Radical en bloc resection, e.g. partial hepatectomy is not generally warranted. If however, removal of a small section of diaphragm, psoas muscle, or tip of the pancreas allows the tumor to be removed intact, this is considered safe and appropriate.
- If it is the surgeons’ judgment that nephrectomy would result in significant or unnecessary morbidity/mortality, diffuse tumor spill, or residual tumor.
- If there is pulmonary compromise due to extensive pulmonary metastases.

The operative principles and operative approach is identical to that described above for a primary unilateral nephrectomy.

Surgical Management of Extrarenal rhabdoid tumor

Extrarenal rhabdoid tumors can be found in a variety of locations, including the soft tissues of the trunk, the extremities, head and neck, abdomen, pelvis and retroperitoneum, as well as in a variety of organs including the thymus, liver, heart and bladder. The same general principles apply when encountering these tumors outside of the kidney as within the kidney. If feasible and safe, the tumor should be completely resected with good margins when first encountered. However, if the initial operation would be associated with significant morbidity (resection of organs or amputation of extremities), adjuvant therapy should be given to shrink the tumor. Such patients would be eligible to participate in the irinotecan/vincristine window study. If the tumor responds to window therapy, the patient can receive 6 weeks of therapy, and be evaluated for second-look surgery. If the tumor does not respond to window therapy, the patient will receive 12 weeks of chemotherapy, then be evaluated for second-look surgery.

Operative Procedure for Bilateral Tumors

Review of NWTSG data found little meaningful staging information was obtained unless the patient was undergoing primary tumor resection, e.g. nephrectomy or partial nephrectomy. Studies have shown a higher risk of local recurrence in patients who had tumor spills or ruptures irrespective of the cause or extent of the soiling. In COG studies, all patients with tumor spill, including biopsy, are considered Stage III. As a result, initial biopsy for bilateral tumors is NOT recommended. However, patients with favorable histology bilateral tumors who do undergo
biopsy may not require radiation therapy unless there are other specific factors that warrant a designation of Stage III, such as lymph node involvement.

There are situations where the radiographic appearance of the tumor may lead to uncertainty in the diagnosis. If the treating clinician wants to obtain a tissue diagnosis before starting therapy, needle biopsies via a posterior approach to limit intraperitoneal spill are preferred. After six weeks of chemotherapy the patient will be re-imaged to determine response to chemotherapy. If there is less than 50% response to the chemotherapy, bilateral open renal biopsies are recommended. Open biopsies are recommended because they are more accurate than percutaneous needle biopsies when assessing anaplasia. The goal of the biopsy is to assess tumor histology of non-responding tumors. The histology of the biopsy will determine whether additional chemotherapy is warranted before proceeding with surgery or if a change in the chemotherapy regimen is needed.

Partial nephrectomy
Assessment of differential renal function prior to surgery is recommended to ensure that the kidney is salvageable. This assessment with radionuclide renal scan (e.g. DMSA scan) should also be repeated after surgery to assess the functional results of the renal sparing procedure. A transperitoneal incision is used. Inspect the renal hilar and periaortic area and sample lymph nodes to rule out lymphatic spread. Palpate the renal vein and IVC for evidence of tumor extension. Do not biopsy the tumor if a partial nephrectomy with margins can be performed since this is a criterion for Stage III. Avoid rupture or spillage by use of an adequate incision. Control of the renal vessels is recommended, but the surgery can be performed without hypothermia or vascular ischemia. In most children, manual compression of the kidney can be used to control bleeding during the dissection. Use of a harmonic scalpel or a similar device may help reduce blood loss and maintain hemostasis, but may interfere with determination of pathology at margins of resection. Gerota’s fascia is opened and the perirenal fat is dissected off the renal surface excluding the fat attached to the mass. A circumferential incision of the renal capsule around the surface of the tumor should be performed and the capsule peeled back to expose the adjacent renal parenchyma. A wedge or guillotine resection of the tumor is performed. The tumor should be excised with a 0.5 to 1 cm rim of normal parenchyma. After removal of the tumor any bleeding vessels can be suture ligated. If there is transection of the collecting system, a watertight closure with fine absorbable suture is recommended.

During the mobilization of the kidney and during dissection of the tumor, care must be taken not to place traction on the renal vessels. Small vessels in young patients are prone to intimal injury which can lead to spasm and subsequent thrombosis.

Following any surgical procedure, if the specimen reveals diffuse anaplasia and there is incomplete resection, additional surgery is indicated to ensure complete resection of the tumor.

Enucleation
Enucleation of the tumor (removal of a tumor from the surrounding tissue) may be the only option for removal of some centrally located tumors. Tumors in this location do not have adjacent renal parenchyma to allow for a partial nephrectomy. These tumors often compress the renal sinus and abut against both the renal vasculature and collecting system. After
chemotherapy, these tumors are often firm with a capsule around the surface of the tumor. This allows for blunt dissection with enucleation of the tumor mass. This procedure should be considered only for patients with **favorable histology** Wilms’ tumor. **If anaplasia is present, enucleation is contraindicated.** Clear margins are mandated for anaplastic tumors.

The surgical approach for enucleation is the same as for partial nephrectomy. A transperitoneal incision is used. Inspect the renal hilar and periaortic area and sample lymph nodes to rule out lymphatic spread. Palpate the renal vein and IVC for evidence of tumor extension. Do not biopsy the tumor if a partial nephrectomy with margins can be performed since this is a criterion for Stage III. During the mobilization of the kidney and during dissection of the tumor, care must be taken not to place traction on the renal vessels. Small vessels in young patients are prone to intimal injury which can lead to spasm and subsequent thrombosis.

**Indications for Nephrectomy with Bilateral Disease**

- Bilateral Wilms’ tumor: partial nephrectomy is not feasible after 12 weeks of chemotherapy.
- Unilateral Wilms’ tumor at high risk for bilateral Wilms’ tumor:
  - a. partial nephrectomy is not feasible after six weeks of chemotherapy and there has been less than a 50% response to chemotherapy.
  - b. partial nephrectomy is not feasible after 12 weeks of chemotherapy.

A generous transabdominal, transperitoneal or thoracoabdominal incision is recommended for adequate exposure. Complete exploration of the abdomen should be performed. To expose the primary tumor the lateral peritoneal reflection is then opened, and the colon is reflected medially. A radical nephrectomy is performed with the dissection plane established outside of Gerota’s fascia. Before mobilizing the primary tumor, an attempt should be made to dissect, expose and ligate the renal vessels in order to lessen the chance of hematogenous spread of tumor cells while removing the tumor. **Preliminary ligation should not be pursued if technically difficult or dangerous.** The adrenal gland may be left in place if it is not abutting the tumor; but, if the mass arises in the upper pole of the kidney, the adrenal gland should be removed with the neoplasm. The ureter is ligated and divided as low as conveniently possible but it is not necessary to remove the entire ureter. The tumor and the uninvolved portion of the kidney are mobilized and removed intact. Any enlarged or suspicious lymph nodes should be included with the specimen.

The use of titanium clips is strongly recommended to identify gross residual tumor. Clips should not be used for hemostasis and those placed for roentgenographic identification or radiation therapy portals should be limited to the minimum number necessary. Metallic clips can interfere with the CT scan. Clips are best applied by placing a non-absorbable suture in the structure to be marked, and attaching the clip to the suture. In general, four small clips should be sufficient to delineate the margins of the tumor.

Any suspicious area that could represent metastases should be biopsied, the site(s) identified with small titanium clips so that the locations can be determined later by roentgenograms. The involved areas should be drawn on the diagram in the surgical checklist. The specimen should be specifically identified as to the site from which it was removed.